...
首页> 外文期刊>Neuropsychopharmacology >Candidate Genes Expression Profile Associated with Antidepressants Response in the GENDEP Study: Differentiating between Baseline |[lsquo]|Predictors|[rsquo]| and Longitudinal |[lsquo]|Targets|[rsquo]|
【24h】

Candidate Genes Expression Profile Associated with Antidepressants Response in the GENDEP Study: Differentiating between Baseline |[lsquo]|Predictors|[rsquo]| and Longitudinal |[lsquo]|Targets|[rsquo]|

机译:GENDEP研究中与抗抑郁药反应相关的候选基因表达谱:区分基线| [lsquo] | Predictors | [rsquo] |和纵向| [lsquo] |目标| [rsquo] |

获取原文

摘要

To improve the ‘personalized-medicine’ approach to the treatment of depression, we need to identify biomarkers that, assessed before starting treatment, predict future response to antidepressants (‘predictors’), as well as biomarkers that are targeted by antidepressants and change longitudinally during the treatment (‘targets’). In this study, we tested the leukocyte mRNA expression levels of genes belonging to glucocorticoid receptor (GR) function (FKBP-4, FKBP-5, and GR), inflammation (interleukin (IL)-1α, IL-1β, IL-4, IL-6, IL-7, IL-8, IL-10, macrophage inhibiting factor (MIF), and tumor necrosis factor (TNF)-α), and neuroplasticity (brain-derived neurotrophic factor (BDNF), p11 and VGF), in healthy controls (n=34) and depressed patients (n=74), before and after 8 weeks of treatment with escitalopram or nortriptyline, as part of the Genome-based Therapeutic Drugs for Depression study. Non-responders had higher baseline mRNA levels of IL-1β (+33%), MIF (+48%), and TNF-α (+39%). Antidepressants reduced the levels of IL-1β (?6%) and MIF (?24%), and increased the levels of GR (+5%) and p11 (+8%), but these changes were not associated with treatment response. In contrast, successful antidepressant response was associated with a reduction in the levels of IL-6 (?9%) and of FKBP5 (?11%), and with an increase in the levels of BDNF (+48%) and VGF (+20%)—that is, response was associated with changes in genes that did not predict, at the baseline, the response. Our findings indicate a dissociation between ‘predictors’ and ‘targets’ of antidepressant responders. Indeed, while higher levels of proinflammatory cytokines predict lack of future response to antidepressants, changes in inflammation associated with antidepressant response are not reflected by all cytokines at the same time. In contrast, modulation of the GR complex and of neuroplasticity is needed to observe a therapeutic antidepressant effect.
机译:为了改善治疗抑郁症的“个性化药物”方法,我们需要确定在开始治疗之前进行评估的生物标志物,以预测抗抑郁药的未来反应(“预测因子”),以及抗抑郁药靶向并纵向改变的生物标志物在治疗期间(“目标”)。在这项研究中,我们测试了糖皮质激素受体(GR)功能(FKBP-4,FKBP-5和GR),炎症(白介素(IL)-1α,IL-1β,IL-4)的基因白细胞mRNA表达水平,IL-6,IL-7,IL-8,IL-10,巨噬细胞抑制因子(MIF)和肿瘤坏死因子(TNF)-α)和神经可塑性(脑源性神经营养因子(BDNF),p11和VGF ),依西酞普兰或去甲替林治疗8周之前和之后的健康对照组(n = 34)和抑郁症患者(n = 74),这是基于基因组的抑郁症治疗药物研究的一部分。无反应者的基线IL-1β(+33 %),MIF(+48 %)和TNF-α(+39 %)的基线mRNA水平较高。抗抑郁药降低了IL-1β(?6 %)和MIF(?24 %)的水平,并增加了GR(+5 %)和p11(+8 %)的水平,但这些变化没有关联与治疗反应。相反,成功的抗抑郁反应与IL-6(?9 %)和FKBP5(?11 %)水平的降低以及BDNF(+48 %)和BDNF水平的提高有关。 VGF(+ 20%)-也就是说,反应与在基线时无法预测反应的基因变化相关。我们的研究结果表明抗抑郁药物的“预测因素”与“目标”之间没有关联。确实,尽管较高水平的促炎细胞因子预示着未来对抗抑郁药缺乏反应,但与抗抑郁药反应相关的炎症变化并未同时反映在所有细胞因子上。相反,需要调节GR复合物和神经可塑性以观察治疗性抗抑郁作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号